LifeVantage Corporation (LFVN) Stock

LifeVantage Corporation (LFVN) is a Healthcare stock trading at $6.47 (as of 2026-06-18), with a market capitalization of $99.29M and a trailing P/E of 14.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.

Valuation — source: SEC EDGAR (first-party)
Price$6.47
Market Cap$99.29M
P/E Ratio14.2
EV / EBITDA7.3
Price / Book2.43
Price / Sales0.41
Dividend Yield2.8%
DCF Value (model)$13.09
DCF Upside vs Price102.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$228.53M
Net Margin4.3%
Return on Equity17.3%
Current Ratio1.96
Revenue Growth (YoY)-25.2%
EPS Growth (YoY)-60.7%
FCF Growth (YoY)-69.6%
Financial Health — source: SEC EDGAR
Altman Z-Score3.42 (safe)
Valuation vs Sector & Industry
Stock P/E14.2
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-31.8%
vs Industry-16.3%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderCAPITAL MANAGEMENT CORP /VA ($10.55M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSteven R. Fife
Employees222
CountryUS
IPO Date1994-04-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Neonc Technologies Holdings, Inc. (NTHI)
  • SAB Biotherapeutics, Inc. (SABS)
  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Minerva Neurosciences, Inc. (NERV)
  • Alector, Inc. (ALEC)
  • Coherus Oncology, Inc. (CHRS)
  • Genelux Corporation (GNLX)
  • Caribou Biosciences, Inc. (CRBU)
LFVN earnings history · LFVN institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.